Holen Sie sich die Stockscreener-App
17.89
1.08%
-0.17
Schlusskurs vom Vortag:
$18.06
Offen:
$18.1
24-Stunden-Volumen:
53,647
Relative Volume:
0.11
Marktkapitalisierung:
$1.34B
Einnahmen:
$62.71M
Nettoeinkommen (Verlust:
$-112.51M
KGV:
-11.85
EPS:
-1.51
Netto-Cashflow:
$-96.01M
1W Leistung:
+7.07%
1M Leistung:
+13.50%
6M Leistung:
+68.06%
1J Leistung:
+35.34%
1-Tages-Spanne:
$17.88
$18.49
1-Wochen-Bereich:
$16.20
$18.49
52-Wochen-Spanne:
$9.03
$18.49
Zymeworks Inc. Stock (ZYME) Company Profile
Firmenname
Zymeworks Inc.
Sektor
Branche
Telefon
604-678-1388
Adresse
1385 West 8th Avenue, Suite 540, Vancouver, BC
Vergleichen Sie ZYME mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
17.89 | 1.37B | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.28 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.63 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.19 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
800.57 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
328.93 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | B. Riley Securities | Buy |
| 2025-05-20 | Eingeleitet | TD Cowen | Buy |
| 2024-12-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Fortgesetzt | Wells Fargo | Overweight |
| 2023-01-04 | Bestätigt | H.C. Wainwright | Neutral |
| 2022-12-20 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-05-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-03-15 | Eingeleitet | Evercore ISI | Outperform |
| 2021-12-10 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-02-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-08-06 | Eingeleitet | SVB Leerink | Outperform |
| 2020-01-10 | Eingeleitet | Wolfe Research | Outperform |
| 2019-12-09 | Eingeleitet | JP Morgan | Neutral |
| 2019-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-30 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Eingeleitet | Stifel | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Zymeworks Inc. Aktie (ZYME) Neueste Nachrichten
What the charts say about Zymeworks Inc. todayWeekly Stock Summary & Short-Term Trading Opportunity Alerts - newser.com
How Zymeworks Inc. stock compares to market leadersSwing Trade & Fast Momentum Stock Entry Tips - newser.com
Is Zymeworks Inc. showing signs of accumulationForecast Cut & Short-Term Trading Alerts - newser.com
Will Zymeworks’ (ZYME) New R&D Leadership Mark a Turning Point in Its Oncology Strategy? - Yahoo
Zymeworks (NYSE:ZYME) Stock Price Up 7.2%Here's What Happened - MarketBeat
Zymeworks (NASDAQ:ZYME) Reaches New 52-Week HighHere's Why - MarketBeat
Zymeworks stock hits 52-week high at 17.71 USD By Investing.com - Investing.com Canada
How Might ZYME’s Shifting Leadership Shape Its Late-Stage Oncology Ambitions? - simplywall.st
B. Riley Securities Initiates Coverage of Zymeworks (ZYME) with Buy Recommendation - Nasdaq
Zymeworks stock hits 52-week high at 17.71 USD - Investing.com
Zymeworks (ZYME) Coverage Initiated by B. Riley Securities with 'Buy' Rating | ZYME Stock News - GuruFocus
Lifesci Capital Forecasts Zymeworks' Q3 Earnings (NYSE:ZYME) - MarketBeat
What technical models suggest about Zymeworks Inc.’s comebackPortfolio Performance Report & Daily Volume Surge Signals - newser.com
Zymeworks appoints Adam Schayowitz as acting chief development officer By Investing.com - Investing.com Nigeria
Will Zymeworks Inc. stock outperform growth indexes2025 Investor Takeaways & Daily Technical Stock Forecast Reports - newser.com
Zymeworks Appoints New Acting Chief Development Officer to Boost Therapeutic Advancements - TipRanks
Zymeworks appoints Adam Schayowitz as acting chief development officer - Investing.com India
Zymeworks Inc. Appoints Adam Schayowitz, Ph.D., MBA as Acting Chief Development Officer - Quiver Quantitative
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer - Stock Titan
Q1 Earnings Forecast for Zymeworks Issued By Lifesci Capital - MarketBeat
How to forecast Zymeworks Inc. trends using time series2025 Dividend Review & Community Consensus Trade Alerts - newser.com
Is Zymeworks Inc a good long term investmentShort-Term Trading Alerts & Small Capital Trading Plans - earlytimes.in
Is Zymeworks Inc. stock entering bullish territoryPortfolio Risk Report & Free Fast Gain Swing Trade Alerts - newser.com
Why analysts maintain buy rating on Zymeworks Inc. (ZA8) stockJuly 2025 Patterns & Precise Swing Trade Entry Alerts - newser.com
Market reaction to Zymeworks Inc.’s recent news2025 Dividend Review & Technical Buy Zone Confirmation - newser.com
Key resistance and support levels for Zymeworks Inc.Quarterly Portfolio Review & Reliable Entry Point Alerts - newser.com
Zymeworks (ZYME): Assessing Valuation Following Recent Momentum in Biopharma - Sahm
Will Zymeworks Inc. stock outperform tech sector in 2025July 2025 Analyst Calls & Scalable Portfolio Growth Ideas - newser.com
Will Zymeworks Inc. stock recover faster than peersQuarterly Profit Summary & Daily Volume Surge Signals - newser.com
How Zymeworks Inc. (ZA8) stock stacks up against competitorsJuly 2025 Fed Impact & Fast Gain Swing Trade Alerts - newser.com
Zymeworks Inc Stock Analysis and ForecastMACD Histogram Signals & Get Tomorrow’s Winners Today With AI - earlytimes.in
Platinum Investment Management Ltd. Decreases Stake in Zymeworks Inc. $ZYME - MarketBeat
What indicators show strength in Zymeworks Inc.Trade Entry Summary & Weekly Watchlist of Top Performers - newser.com
Voya Investment Management LLC Sells 43,861 Shares of Zymeworks Inc. $ZYME - MarketBeat
What drives Zymeworks Inc stock priceStock Valuation Metrics & Exceptional Capital Investment - earlytimes.in
What analysts say about Zymeworks Inc stockTrading Psychology Tips & Rapid Portfolio Investment - earlytimes.in
Published on: 2025-09-30 00:00:12 - newser.com
Finanzdaten der Zymeworks Inc.-Aktie (ZYME)
Umsatz
Nettogewinn
Free Cashflow
ENV
Zymeworks Inc.-Aktie (ZYME) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | Director |
May 19 '25 |
Buy |
11.78 |
5,919 |
69,738 |
17,883,908 |
| EcoR1 Capital, LLC | Director |
Apr 16 '25 |
Buy |
11.16 |
73,953 |
825,589 |
17,773,727 |
| EcoR1 Capital, LLC | Director |
Apr 17 '25 |
Buy |
11.52 |
54,760 |
630,819 |
17,828,487 |
| EcoR1 Capital, LLC | Director |
Apr 04 '25 |
Buy |
11.17 |
196,438 |
2,193,800 |
17,699,774 |
| EcoR1 Capital, LLC | Director |
Apr 03 '25 |
Buy |
11.84 |
120,770 |
1,430,170 |
17,503,336 |
| EcoR1 Capital, LLC | Director |
Apr 02 '25 |
Buy |
11.85 |
74,360 |
881,017 |
17,382,566 |
| EcoR1 Capital, LLC | Director |
Apr 01 '25 |
Buy |
11.60 |
48,658 |
564,647 |
17,308,206 |
| EcoR1 Capital, LLC | Director |
Mar 31 '25 |
Buy |
11.75 |
4,397 |
51,658 |
17,259,548 |
| EcoR1 Capital, LLC | Director |
Mar 25 '25 |
Buy |
12.91 |
53,501 |
690,452 |
17,211,303 |
| EcoR1 Capital, LLC | Director |
Mar 26 '25 |
Buy |
12.24 |
43,848 |
536,857 |
17,255,151 |
0.11%
2.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):